Nifty 17938.4 (-0.96%)
Sensex 60098.82 (-1.08%)
Nifty Bank 38041.35 (-0.44%)
Nifty IT 37281.7 (-2.13%)
Nifty Financial Services 18269.95 (-1.08%)
Adani Ports 744.20 (-2.46%)
Asian Paints 3280.40 (-2.77%)
Axis Bank 729.60 (0.61%)
B P C L 394.35 (-0.94%)
Bajaj Auto 3436.80 (1.05%)
Bajaj Finance 7571.80 (-2.22%)
Bajaj Finserv 18077.30 (-0.42%)
Bharti Airtel 703.70 (-1.49%)
Britannia Inds. 3575.65 (-1.28%)
Cipla 895.65 (-0.72%)
Coal India 163.90 (1.93%)
Divis Lab. 4481.50 (-1.01%)
Dr Reddys Labs 4684.95 (-0.18%)
Eicher Motors 2718.70 (-0.64%)
Grasim Inds 1806.50 (-2.47%)
H D F C 2620.25 (-1.59%)
HCL Technologies 1199.20 (-1.68%)
HDFC Bank 1518.45 (-0.71%)
HDFC Life Insur. 656.05 (-1.95%)
Hero Motocorp 2699.80 (0.26%)
Hind. Unilever 2309.90 (-2.52%)
Hindalco Inds. 504.80 (1.77%)
I O C L 125.10 (0.93%)
ICICI Bank 808.60 (-1.76%)
IndusInd Bank 893.25 (-0.71%)
Infosys 1867.05 (-2.80%)
ITC 220.35 (-0.18%)
JSW Steel 674.65 (-0.82%)
Kotak Mah. Bank 1905.65 (-1.88%)
Larsen & Toubro 2020.90 (-0.06%)
M & M 894.40 (0.25%)
Maruti Suzuki 8015.70 (1.27%)
Nestle India 18937.00 (-2.28%)
NTPC 134.80 (-0.15%)
O N G C 170.25 (3.91%)
Power Grid Corpn 204.65 (-0.24%)
Reliance Industr 2521.60 (-0.01%)
SBI Life Insuran 1248.10 (-1.41%)
Shree Cement 26402.25 (-2.77%)
St Bk of India 515.80 (1.78%)
Sun Pharma.Inds. 838.50 (-0.97%)
Tata Consumer 717.65 (-1.89%)
Tata Motors 520.85 (1.97%)
Tata Steel 1209.60 (1.23%)
TCS 3914.65 (-1.90%)
Tech Mahindra 1670.10 (0.56%)
Titan Company 2588.90 (-0.45%)
UltraTech Cem. 7434.40 (-1.61%)
UPL 813.25 (1.77%)
Wipro 621.15 (-1.92%)
ALEMBICLTD

Alembic Ltd.

₹103.95

Investment Ratings

  • Master Rating:
  • Alembic (Nse) has an operating revenue of Rs. 83.71 Cr. on a trailing 12-month basis. An annual revenue de-growth of -50% needs improvement, Pre-tax margin of 23% is great, ROE of 14% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 200DMA and close to its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 71 which is a FAIR score but needs to improve its earnings, a RS Rating of 9 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 157 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of D is close to being the worst. Overall, the stock has some relative strength and buyer demand but we want to see further fundamental performance to qualify as a growth stock.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Recommendation HoldBuy Sell

Result Highlights

Alembic Ltd Synopsis

NSE-Medical-Diversified

Alembic Ltd. is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 72.30 Cr. and Equity Capital is Rs. 51.36 Cr. for the Year ended 31/03/2021. Alembic Ltd. is a Public Limited Listed company incorporated on 30/07/1907 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L26100GJ1907PLC000033 and registration number is 000033.
  • Market Cap

    INR 2,669.25 Cr

  • Sales

    INR 82.20 Cr

  • Shares in Float

    7.45 Cr

  • No of Funds

    40 K

  • Yield

    0.19%

  • Book Value

    3.23

  • U/D Vol Ratio

    1.8

  • LTDebt/Equity

    %

  • Alpha

    -0.06

  • Beta

    0.86

Alembic Ltd Ownership
Alembic Ltd Management

Alembic Ltd Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Eps And Sales Estimates

Alembic Ltd Financials

INDICATORMar 2021Mar 2020Mar 2019Mar 2018Mar 2017
Total ShareHolders Funds Annual Cr 826.82483.10412.42448.69367.72
Fixed Assets Annual Cr 266.97228.11209.10179.04171.58
Total Non Current Assets Annual Cr 836.84371.69370.97335.27257.39
Total Current Assets Annual Cr 99.62162.5998.77185.37191.28
Total Assets Annual Cr 936.45534.28469.74521.96448.67
INDICATORMar 2021Mar 2020Mar 2019Mar 2018Mar 2017
Book Value Per Share Annual Rs 32.2018.8116.0616.8013.77
ROE Annual % 1.6119.369.969.317.47
ROCE Annual % 1.9119.2110.669.588.57
Total Debt to Total Equity Annual -----
EBDIT Annual Margin % 28.62131.8838.3938.3326.86

Alembic Ltd Technicals

EMA & SMA

CURRENT PRICE

103.95 (-0.34)

    • Bullish Moving Averages 0
    • Bearish Moving Averages 16

EMA

  • 20 Day

    105.8

  • 50 Day

    105.6

  • 100 Day

    108.15

  • 200 Day

    114.5

Alembic Ltd Resistance and support

104.92 PIVOT

  • First Resistance

    106.34

  • Second Resistance

    108.37

  • Third Resistance

    109.79

  • First Support

    102.89

  • Second Support

    101.47

  • Third Support

    99.44

  • RSI

    45.23

  • MFI

    74.66

  • MACD

    0.66

  • MACD signal line

    1.13

Alembic Ltd Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 166,378 7,784,827 46.79%
Week 194,058 9,832,929 50.67%
1 Month 342,603 13,697,279 39.98%
6 Month 546,959 17,179,990 31.41%

Alembic Ltd Price change analysis

5.4

Over 1 month

Low High
94.4 114.8

-6.55

Over 3 month

Low High
90.35 114.8

-31.7

Over 6 months

Low High
90.35 137.4

1.05

Over Year

Low High
90.35 143.3

Corporate Action

Date Purpose Remarks
2021-11-12 Quarterly Results
2021-08-06 Quarterly Results
2021-05-11 Audited Results & Final Dividend
2021-01-28 Quarterly Results
2020-11-03 Quarterly Results

MF Shareholding

Similar Stocks

News

ALEMBIC LTD. - 506235 - Compliances-Reg. 39 (3) - Details of

Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange Read More

ALEMBIC LTD. - 506235 - Shareholding for the Period Ended De

Alembic Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2021. For more details, kindly Click here Read More

ALEMBIC LTD. - 506235 - Compliances-Reg. 39 (3) - Details of

Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange Read More

Alembic gets USFDA nod to market generic product

The company has received tentative approval from the US Food Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Read More

ALEMBIC LTD. - 506235 - Compliances-Reg. 39 (3) - Details of

Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange Read More

FAQs

Stock Directory-

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All 0-9